Astria Therapeutics to Present at Eastern Allergy Conference on Hereditary Angioedema Trial Results

Reuters
22 May
Astria <a href="https://laohu8.com/S/LENZ">Therapeutics</a> to Present at Eastern Allergy Conference on Hereditary Angioedema Trial Results

Astria Therapeutics Inc., a biopharmaceutical company focused on therapies for allergic and immunologic diseases, will present at the Eastern Allergy Conference in Palm Beach, Florida, on May 30, 2025. Dr. Raffi Tachdjian from UCLA will present data on the reduction of attack severity in patients with Hereditary Angioedema from the ALPHA-STAR Phase 1b/2 trial of navenibart.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Astria Therapeutics Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20250522021546) on May 22, 2025, and is solely responsible for the information contained therein.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10